Treasury weighs screening investments in China biotechnews2026-06-18T16:47:52+00:00June 18th, 2026|Endpoints News|
Biogen makes up to $1B deal for secretive anti-inflammatory biotechnews2026-06-18T00:43:13+00:00June 18th, 2026|Endpoints News|
Jazz turns to AbCellera for T cell engagers in up to $4.1B partnershipnews2026-06-17T11:00:12+00:00June 17th, 2026|Endpoints News|
GSK took advantage of ASCO dip to get discount on Nuvalentnews2026-06-12T11:14:14+00:00June 12th, 2026|Endpoints News|
Sciwind has two Western partners for its obesity drug, but is open to morenews2026-06-12T09:00:41+00:00June 12th, 2026|Endpoints News|
Kardigan plans $320M IPO for heart drugs as Nasdaq listings gain steamnews2026-06-11T13:32:29+00:00June 11th, 2026|Endpoints News|
Parabilis CEO Mathai Mammen on biotech’s record IPOnews2026-06-10T17:24:13+00:00June 10th, 2026|Endpoints News|
Novartis and Orionis strike second molecular glue deal for $40M upfrontnews2026-06-10T15:34:24+00:00June 10th, 2026|Endpoints News|
Biotech pay analysis: 12 execs with $35M+ M&A golden parachutesnews2026-06-10T14:00:59+00:00June 10th, 2026|Endpoints News|
GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6Bnews2026-06-09T06:39:59+00:00June 9th, 2026|Endpoints News|
